Little but very meaningful gestures like this one are enough to restore and boost anyone's faith in the NHS! Thank you Cardiology Hampshire Hospitals for this precious and warm welcome-back gift On the left are all the jobs I had done along my journey to become a Consultant Cardiologist!

Cardiac cath report from mid 1970s Note to self: heroin pre-med --> heavy sedation...😆 #cardiotwitter #MedTwitter

➡️TAVI to Treat Degenerated Aortic, Mitral and Tricuspid Bioprosthesis 🎯Review of evidence & procedural considerations for using TAVI device in managing degenerated aortic, mitral, or tricuspid prosthesis. 🔗mdpi.com/2077-0383/13/2… PCRonline 🫀 BCIS EssexCTC Imperial NHS 💙

Divaka Perera Haseeb Rahman Holly Kalpa De Silva Howie Ellis Ozan M. Demir Matthew Li Kam Wa Matt Ryan Saad Ezad Bashir Alaour Sam McGrath

➡️10-year outcomes from NOTION Trial Below are TAVR (SEV) vs SAVR outcomes: 🎯 Severe SVD = 1.5% vs 10% (P=.02) 🎯 Severe NSVD = 20.5% vs 43% (P< .001) 🎯Endocarditis = 7.2% vs 7.4% (P=1.0) 🎯 Bioprosthetic valve failure = 9.7% vs 13.8% (P=.4). 🔗 doi.org/10.1093/eurhea…

Bleeding After Transcatheter Aortic Valve Replacement: The Pebble and the Ripple" Sharing our recently published editorial JACC Journals Stefan Stortecky doi.org/10.1016/j.jcin…

🩸 Exciting findings in #JACCINT! 🫀 Study compares #DOACs & VKAs post-TAVR. 🔄 No significant difference in safety at 30 days, 1, & 5 years. VKAs linked to ⬆️ mortality but ⬇️ disabling stroke. 🤔 VKAs vs DOACs: The #TAVR debate continues bit.ly/49Aj0fz

Very sad to hear this A true pioneer in medicine that helped transform countless peoples' lives, and a great guy Like many societies, in 2022 we welcomed him to London for the 20th anniversary of his first-in-man TAVI A humble, funny & generous man who leaves us too soon 😔

Delighted to share our paper in Open Heart - a meta-analysis on the Comparison of troponin and natriuretic peptides in Takotsubo syndrome and acute coronary syndrome by Liam Couch with colleagues across Royal Brompton and Harefield RDM Oxford King's BHF Centre openheart.bmj.com/content/11/1/e…

Non–vitamin K antagonist vs vitamin K antagonist oral anticoagulant agents after #TAVR Up to 50 % of patients undergoing #TAVI have concomitant indications for long-term oral anticoagulation (OAC) therapy. In many clinical scenarios, DOACs are preferred over VKAs due to an

Literally "per aspera ad astra"! When cardiology research is up near the stars and the limit is beyond the sky! Congratulations Thomas Pilgrim et al.

Really interesting results and external validation of previous work by #KCL team. 🔗ahajournals.org/doi/10.1161/JA… ➡️Coronary slow flow not associated with abnormal CFR or microvascular resistance. Divaka Perera Haseeb Rahman Aish Sinha Cardiac Research

The extent of extra-valvular cardiac damage before and after TAVR and changes in cardiac damage early after TAVR have important implications during long-term follow-up. authors.elsevier.com/a/1izXK6uPJvuU… Masaaki Nakase; Daijiro Tomii; Fabien Praz; Stefan Stortecky

Cardiac damage staging in aortic stenosis is ready for prime time. Excellent Editorial by Philippe Pibarot. sciencedirect.com/science/articl… Masaaki Nakase Daijiro Tomii Fabien Praz

Thomas Pilgrim (Thomas Pilgrim) shares his #QuickTake on the risk of cardiac arrhythmia among men climbing Mount Everest, as seen in the SUMMIT study. Check out the full video here: tctmd.com/videos/tctmds-…

The diagnosis of AS marks the beginning of a life-long journey during which symptoms, expectations and management options are more spectromatic than dichotomous, and more versatile than resolute "Challenges in the life time management of AS" Thomas Pilgrim cvm.swisshealthweb.ch/en/article/doi…

Honoured to have been awarded the #BCS2024 Young Investigator Award for my work on patients with ANOCA. Extremely grateful for the unparalleled mentorship from Divaka Perera and the support from the entire team at Cardiac Research

Presented today at European Society of Cardiology #ESC24 and simultaneously published in JAMA Cardiology, the results of the #PACMAN-AMI lesion-level analysis are now out: incremental plaque burden reduction at lesion-level and MLA site, with evolution of TCFAs and LRPs into more stable plaques